CTLA4 and melanoma: These researchers demonstrated that anti-RANKL and anti-CTLA-4 mAbs have modest antimetastatic activity when applied alone in a preclinical mouse model of B16F10 melanoma with experimental metastases, but the metastasis suppression was significantly improved when these drugs were used in combination at the time of intravenous melanoma inoculation [224].